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Abstract Positional cloning is the approach of choice for
the identification of genetic mutations underlying the
pathological development of diseases with simple Mende-
lian inheritance. It consists of different consecutive steps,
starting with recruitment of patients and DNA collection,
that are critical to the overall process. A genetic analysis of
the enrolled patients and their families is performed, based
on genetic recombination frequencies generated by meiotic
cross-overs and on genome-wide molecular studies, to
define a critical DNA region of interest. This analysis
culminates in a statistical estimate of the probability that
disease features may segregate in the families independent-
ly or in association with specific molecular markers located
in known regions. In this latter case, a marker can be
defined as being linked to the disease manifestations. The
genetic markers define an interval that is a function of their
recombination frequencies with the disease, in which the
disease gene is localised. The identification and character-
isation of chromosome abnormalities as translocations,
deletions and duplications by classical cytogenetic methods
or by the newly developed microarray-based comparative
genomic hybridisation (array CGH) technique may define
extensions and borders of the genomic regions involved.
The step following the definition of a critical genomic region
is the identification of candidate genes that is based on the
analysis of available databases from genome browsers.
Positional cloning culminates in the identification of the
causative gene mutation, and the definition of its functional
role in the pathogenesis of the disorder, by the use of cell-
based or animal-based experiments. More often, positional
cloning ends with the generation of mice with homologous
mutations reproducing the human clinical phenotype. Alto-
gether, positional cloning has represented a fundamental step
in the research on genetic renal disorders, leading to the
definition of several disease mechanisms and allowing a





Positional cloning is one of the most important molecular
approaches to genetic disorders. Since its introduction in
research practice in the early 1980s, it has been widely
utilised for defining the molecular origin of genetic diseases
with Mendelian traits and still represents a necessary
research step in this area. The term identifies a series of
molecular techniques (not a single one) that usually lead,
during successive steps, to the definition of causative genes.
Overall, the strategy of positional cloning starts with the
identification of a candidate gene, according to chromo-
somal location, and is followed by mutation analysis in
affected individuals. The second phase, which follows the
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aimed at defining the causative relationship between a gene
mutation and an aberrant phenotype, very often including in
vitro tests and/or experiments on animal models (Fig. 1).
There are, however, several alternative strategies that allow
the identification of a causative gene, starting from animal
models or from proteomic approaches and that are
nowadays considered as an integral part of positional
cloning. They constitute the so-called inverse genetics, a
term that indicates how genotype identification is followed
by phenotype characterisation, in contrast to “forward
genetics”, in which the study of phenotype leads to
genotype identification [1]. Inverse genetics is gaining
increasing popularity, thanks to the completion of genome
sequencing, the improvement of databases, and the use of
modern proteomic techniques that allow the detection of
even very tiny differences in the proteomes of patients with
respect to control samples. These strategies, already fully
described in the report by Groenen and van den Heuvel [2],
are out of the scope of this teaching section.
There is a long list of renal diseases characterised, over
years, by traditional positional cloning, including the
identification of causative genes of cystic diseases with
dominant (ADPKD1, ADPKD2) and recessive traits,
Alport’s syndrome, nephronophthisis and medullary cystic
diseases. These are only examples of disorders with
relatively frequent occurrence, but the list of rarer con-
ditions is obviously quite long.
As already pointed out, traditional positional cloning
consists of different consecutive steps that will be reviewed
separately.
Patient recruitment and DNA sample collection
An accurate clinical analysis, with proper classification of
patients according to established criteria, is an essential
aspect during this preliminary phase, since a mistake in
interpreting clinical data would cause an inappropriate
classification. In this phase, the disease of interest should
Fig. 1 Main steps in positional cloning of genetic disorders (DHPLC denaturing high-performance liquid chromatography, SSCP single-strand
conformation polymorphism)
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condition, to avoid unnecessary duplication of analysis.
The use of public databases such as GeneClinics (http://
www.geneclinics.org) and OMIM (Online Mendelian In-
heritance in Man, a catalogue of human genes and genetic
disorders, http://www.ncbi.nlm.nih.gov/) facilitates the
search for both clinical aspects and gene mutations
associated with a specific disease. In addition, these
databases indicate available molecular diagnostic tests that
integrate clinical data for a fine classification of patients.
Only conditions that are of new description or for which
responsible genetic mutations are still to be identified are to
be considered for positional cloning. A basic point in this
respect is to consider the clinical variability usually
associated with specific gene mutations that suggests the
extension of the clinical study to family members possibly
sharing one or more clinical signs. The type of inheritance
that is inferred from pedigree analysis indicates segregation
modes that are a key aspect of the problem. It must be
clearly distinguished between simple Mendelian and com-
plex traits, the latter being characterised by mutations/
variants in different genes with often additive effects and
environmental interactions.
DNA samples are then collected from all the members of
interest after informed consent had been obtained.
Positional cloning starting from cytogenetic evidence
A major contribution to the identification of disease genes
comes from studies in patients with chromosome anomalies
that, when present, suggest a direct causative link with the
disease. Balanced translocations or inversions are of
particular interest, since, in principle, they are not associ-
ated with loss or gain of DNA material. Therefore, the
association of an “apparently” balanced translocation/
inversion with an abnormal phenotype may indicate that
the aberration is not really balanced and that a small
quantity of DNA, undetectable by traditional cytogenetic
analysis, has been lost during rearrangement. Alternatively,
a balanced translocation may have interrupted the disease
gene or separated it from an expression regulatory region.
In these cases, cloning of chromosome breakpoints leads to
the identification of the disease-associated gene. The
identification of the gene for polycystic kidney disease
(PKD1) is a good example of this approach [3]. In 1994, in
a Portuguese family with polycystic kidneys, the European
Polycystic Kidney Disease Consortium isolated a gene
encoding a 14-kb transcript that was disrupted by a
chromosome translocation. In this family the mother had a
balanced translocation, 46,XX t(16;22)(p13.3;q11.21),
which had been inherited by her daughter. The mother
and the daughter with the balanced translocation had the
clinical features of PKD1, while the parents of the mother
were cytogenetically normal, with no finding of renal cysts
on ultrasound examination. The consortium isolated a gene
spanning the breakpoint which was found mutated in other
patients with PKD1.
Deletions are other chromosome aberrations that may
favour positional cloning in some conditions. Depending on
the extent of a deletion, few or several genes may be
deleted, which results in multiple-organ effects that identify
a condition also known as “contiguous gene syndrome”.
Mental retardation is often associated with large chromo-
somal deletions.
Interstitial or telomeric chromosome deletions extending
over small regions may be of interest. In general, unlike
translocations, deletion breakpoints may be located at some
distance from the disease gene, confining the search for a
candidate gene to small genomic regions flanked by the
deletion breakpoints. Several patients with de novo mutations
are, in fact, carriers of chromosome alterations, implying that
classical cytogenetic G-banded metaphase chromosome anal-
yses must be performed in the case of de novo mutations.
Microarray-based comparative genomic hybridisation
(array CGH) is a new method allowing the detection of
subliminal chromosome anomalies throughout the genome.
Basically, the method consists of the use of DNA from
matched control and patient cells in competitive fluores-
cence in situ hybridisation on oligonucleotide-array probes
designed in silico. Image-processing software reveal ge-
nomic regions where the ratio between two fluorescence
signals from control and patient DNA deviates from
expectation, indicating gain or loss of DNA material.
Prospective studies have demonstrated that array CGH has
the potential to detect all types of genomic imbalance,
including deletions, duplications, aneuploidies and amplifi-
cations, with detection rates ranging from 5% to 17% in
individuals with normal results from prior routine cytoge-
netic testing [4]. CGH has already achieved great results in
the vast area of the search for genes involved in tumour
development. The recent paper by Rivera et al. [5], who
identified a new gene, WTX (a Wilms’ tumour gene on the
X chromosome), inactivated in sporadic Wilms’ tumours, is
only an example of this application. The authors searched
for DNA copy-number changes in 51 primary tumour
specimens by performing a genome-wide scan with array
CGH. Results indicated small deletions at chromosome
Xq11.1 overlapping the WTX gene in five out of 26 male
patients. By using the more classical fluorescence in situ
hybridization (FISH) cytogenetic analysis, they also
detected heterozygous deletions in six out of 25 female
patients, affecting the active copy of the X chromosomes.
Finally, point mutations were also identified in additional
patients. Notably, no tumour with a deletion or point
mutation in WTX contained mutations in any of the other
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involved in Wilms’ tumours, which suggests that inactiva-
tion of the WTX gene may account for a distinct subset of
nephroblastomas. The importance of the results obtained by
the use of array CGH in identifying disease genes will
encourage its application to the search for genes involved in
renal hereditary diseases.
Positional cloning starting from genetic linkage analysis
A positional approach, based on linkage analysis in families
with multiple affected individuals, is still the method of
choice for identifying rare mutations implicated in simple
Mendelian diseases. For complex traits, which involve
several interacting genes and/or multifactorial mechanisms,
new statistical methods have been set up, based on the
analysis of smaller family units. Transmission analysis of
single or multiple molecular markers in affected sibling
pairs and in trios (simple families composed of parents and
one affected child) is an emerging technique in complex
traits, in addition to comparison of unrelated patients and
controls for population-based association studies. So far,
only limited application of these techniques has been
reported (for reviews see Forabosco et al. [6]).
The logical basis for genetic mapping lies in the
occurrence of genetic recombination of maternal and
paternal homologues, which results from crossing over
during meiosis. Linkage analysis tests whether specific
disease characteristics segregate at meiosis independently
or in association with genetic markers widespread in the
different segments of the human genome. DNA single
nucleotide polymorphisms (SNPs) and short tandem
repeats, also called DNA microsatellites, are utilised as
markers of the segment of DNA of interest. SNPs are the
most common form of DNA sequence variation, occurring
when a single nucleotide—A, T, C, or G—in the genome
differs among individuals or between paired chromosomes
in an individual. Changes can occur in both coding (gene)
and non-coding regions of the genome, most of them
showing no effect on cell function. DNA microsatellite
markers consist of short sequences, typically from one to
four nucleotides, repeated in tandem several times and
therefore forming highly informative multiple alleles. On
the other hand, SNPs are less informative and less useful
for human genetic mapping (Fig. 2). In spite of this, SNPs
have the advantage of being more diffusely present than
microsatellites in the human genome (one every 100 to 300
bases compared with one every 1,000–3,000). In addition,
while microsatellite analysis requires DNA sequencing,
SNPs may be rapidly characterised by using DNA arrays. It
is clear, however, that the choice of using SNP or micro-
satellites in linkage analysis depends on their availability in
the genomic region of interest and on the variability among
the members of families under study [1].
When an association is observed, linkage analysis
defines by statistical probability whether the association
occurs by chance or because the disease gene and the tested
genetic markers are closely located in the same genomic
segment [1, 6].
The principal method of linkage analysis is the calculation
of the logarithm of the odds (lod) score, which is based on the
genetic recombination frequencies generated by meiotic
cross-overs. Since the probability of a cross-over occurring
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Fig. 2 Genetic markers: DNA
single nucleotide polymor-
phisms and microsatellites. a
Example of SNP. Left Fragments
of DNA with the same sequence
containing a difference only in a
single nucleotide. The two
alleles (G and T) give rise to
three possible genotypes: TT
homozygous, T/G heterozygous
and GG homozygous. On the
right-hand side: example of
SNP hypothetical segregation in
a pedigree. b Example of DNA
microsatellite. Left Fragments of
DNA with the same sequence
containing a (CA) microsatellite.
The polymorphism consists of
different numbers of the dinu-
cleotide (CA) present in each of
the four possible alleles repre-
sented (N=10 to N=13). Right
Example of DNA microsatellite
polymorphism hypothetical seg-
regation in a pedigree
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is possible to estimate this latter by means of the frequency of
recombination. If this frequency, known as the recombination
fraction (θ), is small, two loci should be closely located in the
genome. Conversely, when two loci are distant they will
segregate independently and θ will be equal to 50%.
The lod score (Z value) is represented by the logarithm of
the odds ratio between the likelihood that one or more
markers are linked (recombination fraction = θ) or not linked
(recombination fraction = 50%) to the disease phenotype. In
other words, the lod score analysis tests the hypothesis that
the recombination fractions between the genetic markers and
the clinical trait observed are significantly different from
50%, which is the value predicted by the hypothesis of
random association. Non-random association is defined by
values of the lod score equal to or higher than 3.3, a value
actually considered to be the threshold for accepting linkage
with 5% probability of false positive results [6].
In general, linkage analysis indicates the interval in
which the disease gene is localised in close proximity with
the associated markers. The genetic interval is measured in
centimorgans (cM), 1 cM corresponding to a 1% chance of
a recombination event. In terms of physical distance, 1 cM
corresponds, on average, to 1 million DNA base pairs (1
megabase, 1 Mbp). The number of candidate genes that
should be considered for mutation analysis depends on the
size of the candidate region, so that a strong effort is
required to define the smallest candidate region. Usually,
after initial genetic mapping that defines a candidate region
of 10 Mbp, the region is narrowed by increasing the number
of polymorphic markers and, possibly, by looking at other
informative families. In principle, a family with 100
informative meioses might restrict the locus of a Mendelian
disease to a candidate region of approximately 1 cM, that is,
1 million DNA base-pairs that correspond to very few genes.
Identification of a candidate gene
The step that follows the definition of a critical region for a
given disease is the identification of candidate genes. It is
based on the analysis of available databases from genome
browsers such as Ensembl (http://www.ensembl.org)o r
Santa Cruz Genome Browser UCSC (http://genome.ucsc.
edu) that contain large numbers of data covering the whole
genome but few areas that are still to be characterised. In
such cases, alternative strategies should be designed.
Databases contain information on gene maps and specific
expression profiles and, in some cases, provide relevant
hints on functions. For genes not yet cloned, or in the case
of limited expression data in specific tissues, hypothetical
transcripts are defined, as deduced from bio-informatic
tools. Genome browsers provide a considerable number of
data on expression and functions of paralogous and
orthologous genes in different animal species, including
data on mouse mutants that may be essential in the strategy.
Once the list is available, it is necessary to rank genes
endowed in the critical zone on the basis of expression and/
or function consistent with disease development. One
practical criterion is to consider those genes that are
expressed in organs and tissues involved in the disease
phenotype, either during adulthood or embryonic develop-
ment. When not available in databases, expression data
should be generated by new laboratory investigations using
classical and innovative strategies based on reverse tran-
scriptase-polymerase chain reaction (RT-PCR), Northern
blot, in situ hybridisation and expression arrays [1]. Since
it is accepted that humans and mice have similar expression
patterns, many experiments can be carried out on mouse
tissues, especially if the use of embryonic tissues is required.
Other practical approaches for identifying candidate genes
are to consider functions of specific genes and/or, in the case
of similar diseases, functional homologues that are involved
in similar diseases. For example, an ion channel may be a
good candidate for diseases of the renal tubule. Again,
molecules of the cilia may be good candidates for
nephronophthisis and/or other renal cyst diseases.
Search for mutations and functional analysis
The search for functional mutations in a candidate gene is the
stepfollowingpositionalcloning.Thetermmutationdefinesa
change inDNA sequencein a given gene thatisnot present in
the general population. The presence of the mutation is not,
however, ‘per se’, a direct demonstration of a causative rela-
tionshipwithaclinicalphenotype.Infact,causativemutations
should be clearly related to a functional impairment that is
caused by the change itself. Stop codons, frame-shifts,
nonsense mutations and micro-deletions are, in this sense,
most probative of a structural change, since they lead to the
generation of short unstable transcripts and/or short proteins
lacking functional domains. Another piece of evidence
proving a direct involvement in the pathogenesis of the
disease is the demonstration of an aberrant effect in animals.
Among different methods for detecting new mutations
[i.e. single strand conformational polymorphism (SSCP);
heteroduplex analysis (HA)], the most widely utilised are
denaturing high-performance liquid chromatography
(DHPLC) and direct sequencing after PCR amplification
of exon fragments of genomic DNA. DHPLC gives
information about the specific elution profile of variants,
which must then be demonstrated by direct sequencing. It is
a rapid and completely automatic approach and is, for these
reasons, the technique of choice to utilise in screening
studies. Deletions, inversions and/or mutations involving
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difficult to detect. In the former case, the use of more
sophisticated techniques is required. Pulsed-field gel elec-
trophoresis and Southern blot, FISH on chromosome
metaphases and DNA microsatellite analysis with recon-
struction of inherited haplotypes are the techniques of
choice for detecting large molecular deletions. Array CGH
for smaller deletions has been described above. Intronic
mutations may be involved in the splicing of the mature
transcripts and, therefore, affect expression. Splicing errors
of RNA molecules, as well as mutations affecting more, in
general, transcription regulatory sequences, may be
detected by RT-PCR in tissues in which the candidate gene
is expressed (see [7] for an overview on the RNA
maturation process and RT-PCR technique). Briefly, the
method consists of a first step that includes reverse
transcription, followed by PCR amplification, of an
expressed gene using its RNA, instead of genomic DNA,
as starting material. By using this technique one can
directly and quite rapidly test a gene of interest for
mutations possibly impairing its qualitative or quantitative
expression, as mutations in transcription regulatory sequen-
ces or in sites regulating RNA splicing may do. Unfortu-
nately, this approach is often confined to genes expressed in
blood cells or fibroblasts, because of their accessibility,
while the definition of splicing mutations in target organs is
limited, due to tissue sampling. A key point of positional
cloning that should always be kept in mind is that there are
mutations with no clear functional effects that cannot be
readily related to the pathogenesis of a disease. In general,
they are missense mutations, causing only minor changes in
DNA sequence without relevant effects on gene expression
and function. Owing to their minor impact on gene
function, the distinction between missense mutations and
rare neutral variants may be, in some cases, difficult and
require screening studies in a general population. Function-
al tests carried out in cells and based on in vitro techniques
are required in these cases to confirm a relationship with
human pathology. Expression studies involve transfection
of cell lines with a mutated cloned cDNA and are mainly
based on functional tests searching for impairment of cell
physiology. An alternative to the use of cDNA cloned in the
laboratory is the use of cells deriving from patients
presenting the basic defect. In general, cell experiments
require positive and negative (i.e. wild type cells) controls.
Sometimes, it is possible to rescue the abnormal cell
phenotype by transfecting the mutated cells with a wild
type form of the gene, obtaining a confirmation of the
pathogenetic mechanisms.
As already discussed, experiments on animals are
necessary for final validation. They consist of definitive
suppression (knock out) of a gene and are, in some cases,
based on the generation of animal strains incorporating the
same mutations observed in humans (knock in) [8]. Several
spontaneous, chemically-induced or transgenic mouse
mutants have been generated in the past few years and are
maintained in animal facilities (such as The Jackson
Laboratories in the USA, http://www.jax.org/ and the
EMMA archive in Europe, http://www.emma.rm.cnr.it/).
Chemical mutagenesis causing random allelic point muta-
tions in mice is, nowadays, a promising technique for
creating animal models of human diseases. The most
popular method to obtain chemical mutagenesis is the use
of N-ethyl nitroso-urea (ENU), which has been widely
utilised to create abnormal phenotypes. ENU mice have
already been generated and characterised on a phenotypic
basis by international consortiums and are available on
request. Therefore, the advantage of ENU mice is their
clinical characterisation, while their drawback is the lack of
genetic information, which requires a lot of molecular
work. Phenotype screenings and genetic and molecular
analyses of ENU mice are now in progress, with the clear
objective of building up an informative system to be
utilised at any occurrence [9].
A key aspect, and probably the major drawback, of
animal models, considering knock-out and knock-in mouse
types, is the phenotype that often does not reflect human
beings.
An emerging alternative to the use of mouse mutagenesis
forfunctional genomicsand disease modellingis represented
by the system of morpholino-phosphorodiamidate-based
anti-sense oligonucleotides (MPOs) for gene-specific
knock-down in Zebrafish (Danio rerio)[ 10].
MPOs, originally developed as therapeutic agents, are
oligonucleotides in which the ribose sugar has been
replaced with a morpholine moiety, and the phospho-diester
linkage between nucleotides has been replaced with a
phospho-rodiamidate non-ionic linkage. When an MPO
hybridises to its target RNA, it is hypothesised to block the
40S ribosomal subunit scanning process, thereby effectively
preventing initiation of translation. MPOs seem to work in
the animal systems where they can be delivered early in
development by micro-injection. The Zebrafish is well
suited as a model organism, due to the ease of delivery by
micro-injection. Other advantages of the use of Zebrafish
are the fast rate of development and the transparency of
embryos, which allows easy visualisation of fundamental
vertebrate developmental processes. Since this teleost,
unlike simple invertebrates, maintains the biological and
genomic complexity found in higher vertebrates, its use in
developmental disorder studies has been increased. Recent-
ly, this system has also been successfully used to obtain
models of renal disorders [11, 12]. Results obtained to date
highlight the efficiency and rapidity of the method and
highly encourage its use as a tool for in vivo function
assessment of vertebrate genomes.
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An example of the successful application of positional
cloning in nephrology is the identification of a gene for a
variant of nephrotic syndrome, recently reported by Hinkes
et al. [12]. These authors utilised haplotype-based linkage
analysis to delimit the critical region to an interval of
4.0 Mb on chromosome 10q23.32–q24.1 that contains 43
predicted genes. Candidate gene selection prior to muta-
tional analysis was based on the hypothesis that nephrotic
syndrome should rely on mutations in a gene expressed in
podocytes. Glomerular DNA expression of the 43 genes of
the critical region was evaluated with microarrays that
demonstrated a reproducible expression profile at this site
for only three genes. Mutational analysis showed different
homozygous nonsense and frameshift mutations of
phospholipase c epsilon (PLCE1) in affected individuals
that predicted the synthesis of truncated forms of the
protein, with loss of function. The confirmation of a
functional implication of PLCE1 in glomeruli was obtained
in Zebrafish in which the plce1 knock-down produced an
altered structure of slit-diaphragm, effacement and disorga-
nisation of podocyte foot processes, with consequent
disruption of the glomerular filtration barrier and oedema.
It is noteworthy that the knock-out mouse model for
PLCE1 reported in 2005, before the finding of mutations
in nephrotic syndrome [13], presented no renal phenotype
and, most importantly, no nephrotic syndrome. The
presence of modifier genes in the mouse strain utilised for
the knock-out of the gene may explain this apparent
contradiction and also gives an idea of the problems that
can be encountered with animal models of human diseases.
The evidence in Zebrafish is sufficient, in this case, to
prove the direct relationship between functional mutations
of PLCE1 and nephrotic syndrome.
Conclusions
Positional cloning based on genome-wide mapping and
candidate gene analysis will probably remain the method of
choice for defining Mendelian traits in the near future.
Among basic requirements that have to be fulfilled prior to
the start of the molecular approach, the availability of
informative families with clear clinical phenotypes still
remains a challenge for researchers. Owing to technology
advancements, an increasing number of molecular tools,
such as adequate DNA markers, information on gene
sequences and expression profiles and functions, will allow
the extension of positional cloning to those conditions still
lacking molecular characterisation. Multifactorial diseases
represent the new frontier that has to be rapidly faced. The
definition of regulatory mechanisms for gene expression
(transcriptome), a better knowledge of protein structure and
functions (proteome) and new animal models of the disease
are essential topics for future studies.
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